Design, synthesis and structure-activity relationship of 2-(3′,4′,5′-trimethoxybenzoyl)-benzo[b]furan derivatives as a novel class of inhibitors of tubulin polymerization

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 19, 2009, Pages 6862-6871

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Carrion, Maria Dora ^a   Cara, Carlota Lopez ^a   Cruz Lopez, Olga ^a   Tolomeo, Manlio ^b   Grimaudo, Stefania ^b   Cristina, Antonietta Di ^b   Pipitone, Maria Rosaria ^b   Balzarini, Jan ^c   Zonta, Nicola ^d   Brancale, Andrea ^d   Hamel, Ernest ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e Developmental Therapeutics Program   (United States)

Author keywords

Antiproliferative agents; Antitubulin agents; Benzo b furan derivatives; Colchicine; Combretastatin A4

Indexed keywords

(3,4,5 TRIMETHOXYPHENYL)(3 METHYLBENZOFURAN 2 YL)METHANONE; (3,4,5 TRIMETHOXYPHENYL)(5 METHYLBENZOFURAN 2 YL)METHANONE; (4 HYDROXY 3 METHYLBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (4 METHOXY 3 METHYLBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (4 METHOXYBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 BROMOBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 CHLOROBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 HYDROXYBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 METHOXY 3 METHYLBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 METHOXYBENZOFURAN 2 YL)3,4,5 TRIMETHOXYPHENYL)METHANONE; (5,6 DIMETHOXYBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5,6,7 TRIMETHOXYBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (6 ETHOXY 3 METHYLBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (6 FLUORO 3 METHYLBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (6 METHOXY 3 METHYLBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (6 METHOXYBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (7 HYDROXY 6 METHOXYBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (7 HYDROXYBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (7 METHOXY 3 METHYLBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (7 METHOXYBENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (BENZOFURAN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; ANTINEOPLASTIC AGENT; BENZENE; BENZOFURAN DERIVATIVE; COLCHICINE; COMBRETASTATIN A4; HYDROXYL GROUP; METHYL GROUP; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRON TRANSPORT; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; NONHUMAN; SEVERE ACUTE RESPIRATORY SYNDROME; SUBSTITUTION REACTION;

ANTINEOPLASTIC AGENTS; BENZOFURANS; BINDING SITES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; PROTEIN MULTIMERIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS;

EID: 70249124615     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.08.027     Document Type: Article

References (42)

1. Honore S., Pasquier E., and Braguer D. Cell. Mol. Life. Sci. 62 (2005) 3039
2. Hearn B.R., Shaw S.J., and Myles D.C. Comp. Med. Chem. II 7 (2007) 81
3. Pasquier E., Andrè N., and Braguer D. Curr. Cancer Drug Target 7 (2007) 566
4. Pellegrinelli F., and Budman D.R. Cancer Invest. 23 (2005) 264
5. Chaplin D.J., Horsman M.R., and Siemann D.W. Curr. Opin. Invest. Drugs 7 (2006) 522
6. Nam N.H. Curr. Med. Chem. 10 (2003) 1697
7. Li Q., and Sham H.L. Exp. Opin. Ther. Pat. 12 (2002) 1663
8. Beckers T., and Mahboobi S. Drugs Future 28 (2003) 767
9. Ducki S. Anti-cancer Agents Med. Chem. 9 (2009) 336
10. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., and Garcia-Kendall D. Experientia 45 (1989) 209
11. Lin C.M., Ho H.H., Pettit G.R., and Hamel E. Biochemistry 28 (1989) 6984
12. Tron G.C., Pirali T., Sorba G., Pagliai F., Busacca S., and Genazzani A.A. J. Med. Chem. 49 (2006) 3033
13. Mahindroo N., Liou J.P., Chang J.Y., and Hsieh H.P. Exp. Opin. Ther. Pat. 16 (2006) 647
14. Jordan M.A., and Wilson L. Nat. Rev. Cancer 4 (2004) 253
15. Chaudhary A., Pandeya S.N., Kumar P., Sharma P.P., Gupta S., Soni N., Verma K.K., and Bhardwaj G. Mini-Rev. Med. Chem. 7 (2007) 1186
16. Hsie H.P., Liou J.P., and Mahindroo N. Curr. Pharm. Des. 11 (2005) 1655
17. Pettit G.R., Toki B., Herald D.L., Verdier-Pinard P., Boyd M.R., Hamel E., and Pettit R.K. J. Med. Chem. 41 (1998) 1688
18. Liou J.P., Chang C.W., Song J.W., Yang Y.N., Yeh C.F., Tseng H.Y., Lo Y.K., Chang Y.L., Chang C.M., and Hsieh H.P. J. Med. Chem. 45 (2002) 2556
19. Romagnoli R., Baraldi P.G., Sarkar T., Carrion M.D., Cruz-Lopez O., Lopez-Cara C., Tolomeo M., Grimaudo S., Di Cristina A., Pipitone M.R., Balzarini J., Gambari R., Ilaria L., Saletti R., Brancale A., and Hamel E. Bioorg. Med. Chem. 16 (2008) 8419
20. Romagnoli R., Baraldi P.G., Carrion M.D., Lopez Cara C., Preti D., Fruttarolo F., Pavani M.G., Tabrizi M.A., Tolomeo M., Grimaudo S., Di Antonella C., Balzarini J., Hadfield J.A., Brancale A., and Hamel E. J. Med. Chem. 50 (2007) 2273
21. Romagnoli R., Baraldi P.G., Jung M.K., Iaconinoto M.A., Carrion M.D., Preti D., Tabrizi M.A., Fruttarlo F., De Clercq E., Balzarini J., and Hamel E. Bioorg. Med. Chem. Lett. 15 (2005) 4048
22. Romagnoli R., Baraldi P.G., Sarkar T., Carrion M.D., Lopez-Cara C., Cruz-Lopez O., Preti D., Tabrizi M.A., Tolomeo M., Grimaudo S., Di Cristina A., Zonta N., Balzarini J., Brancale A., Hsieh H.P., and Hamel E. J. Med. Chem. 51 (2008) 1464
23. Young S.L., and Chaplin D.J. Exp. Opin. Invest. Drugs 13 (2004) 1171
24. Pettit G.R., Temple Jr. C., Narayanan V.L., Varma R., Boyd M.R., Rener G.A., and Bansal N. Anti-Cancer Drug Des. 10 (1995) 299
25. Flynn B.L., Hamel E., and Jung M.K. J. Med. Chem. 45 (2002) 2670
26. Dupeyre G., Chabot G.G., Thoret S., Cachet X., Seguin J., Guénard D., Tillequin F., Scherman D., Koch M., and Michel S. Bioorg. Med. Chem. 14 (2006) 4410
27. Kozikowski A.P., and Ma D. Tetrahedron Lett. 32 (1991) 3317
28. Hamel E. Cell Biochem. Biophys. 38 (2003) 1
29. Verdier-Pinard P., Lai J.-Y., Yoo H.-D., Yu J., Marquez B., Nagle D.G., Nambu M., White J.D., Falck J.R., Gerwick W.H., Day B.W., and Hamel E. Mol. Pharmacol. 53 (1998) 62
30. Ravelli R.B.G., Gigant B., Curmi P.A., Jourdain I., Lachkar S., Sobel A., and Knossow M. Nature 428 (2004) 198
31. Kong Y., Grembecka J., Edler M.C., Hamel E., Mooberry S.L., Sabat M., Rieger J., and Brown M.L. Chem. Biol. 12 (2005) 1007
32. For the preparation of 5j see:. Foyer R., Rene L., Cavier R., and Lemoine J. Eur. J. Med. Chem. 12 (1977) 455
33. For the preparation of 5k see:. Fukuda Y., Furuta H., Kusama Y., Ebisu H., Oomori Y., and Terashima S. J. Med. Chem. 42 (1999) 1448
34. Compound 5l was synthesized following the procedure:. Wang X., and Porco Jr. J.A. Angew. Chem., Int. Ed. 45 (2006) 6607
35. Compound 5n was prepared following the procedure:. Kemoto H., Miyata J., Yoshida M., Raku N., and Fukumoto K. J. Org. Chem. 62 (1997) 7850
36. For the synthesis of 5s see:. Kagawa H., Shigematsu A., Ohta S., and Harigaya Y. Chem. Pharm. Bull. 53 (2005) 547
37. For the synthesis of 5v:. Zhang X., and Sui Z. Synthesis (2006) 2568
38. For the preparation of 5w see:. Aggarwal R., Giles R.G.F., Green I.R., Oosthuizen F.J., and Taylor C.P. Org. Biomol. Chem. 3 (2005) 263
39. For the synthesis of 5x see:. Bennett C.J., Caldwell S.T., McPhail D.B., Morrice P.C., Duthie G.G., and Hartley R.C. Bioorg. Med. Chem. 12 (2004) 2079
40. Hamel E., and Lin C.M. Biochemistry 23 (1984) 4173
41. Korb O., Stützle T., and Exner T.E. Swarm Intelligence 1 (2007) 115
42. Zonta N., Grimstead I.J., Avis N.J., and Brancale A. J. Mol. Mod. 15 (2009) 193